Analyzing metabolic profiles of blood stem cells in older adults with clonal hematopoiesis
Metabolic Profiling of Hematopoietic Stem Cells in Clonal Hematopoiesis (CHIP): a Prospective Observational Study
This study is trying to see how aging affects blood stem cells in older adults with certain genetic changes, by looking at blood and bone marrow samples taken during hip surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 24 (estimated) |
| Ages | 55 Years and up |
| Sex | All |
| Sponsor | Imelda Hospital, Bonheiden Academic / other |
| Locations | 1 site (Bonheiden, België) |
| Trial ID | NCT05246813 on ClinicalTrials.gov |
What this trial studies
This observational study involves collecting blood and bone marrow samples from patients aged 65 and older who are undergoing hip arthroplasty surgery. The samples will be analyzed for metabolic profiling and to identify mutations associated with clonal hematopoiesis of indeterminate potential (CHIP). Researchers will utilize advanced techniques such as single-cell transcriptomics and mutation-specific genotyping to compare gene expression profiles of normal and mutant hematopoietic stem cells, focusing on metabolic pathways. The goal is to better understand the relationship between aging, metabolic changes, and clonal hematopoiesis.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 65 years and older who are scheduled for hip arthroplasty surgery.
Not a fit: Patients with known hematological conditions such as myelodysplasia, leukemia, or cancer will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into the metabolic changes associated with clonal hematopoiesis, potentially leading to improved management of related conditions in older adults.
How similar studies have performed: While the specific approach of this study may be novel, similar studies have shown promise in understanding the implications of clonal hematopoiesis in aging populations.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 65 years and older Exclusion Criteria: * known haematological condition (myelodysplasia, leukemia, cancer) * inability to provide written informed consent
Where this trial is running
Bonheiden, België
- Imelda Hospital — Bonheiden, België, Belgium (Recruiting)
Study contacts
- Principal investigator: Nick Van Gastel, PhD — de Duve Institute
- Study coordinator: Michaël R. Laurent, MD PhD
- Email: michael.laurent@imelda.be
- Phone: +32485143267
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.